Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method.
Antib Ther
; 6(2): 76-86, 2023 Apr.
Article
in English
| MEDLINE | ID: covidwho-2294418
ABSTRACT
Background:
Rapid and efficient strategies are needed to discover neutralizing antibodies (nAbs) from B cells derived from virus-infected patients.Methods:
Here, we report a high-throughput single-B-cell cloning method for high-throughput isolation of nAbs targeting diverse epitopes on the SARS-CoV-2-RBD (receptor binding domain) from convalescent COVID-19 patients. This method is simple, fast and highly efficient in generating SARS-CoV-2-neutralizing antibodies from COVID-19 patients' B cells.Results:
Using this method, we have developed multiple nAbs against distinct SARS-CoV-2-RBD epitopes. CryoEM and crystallography revealed precisely how they bind RBD. In live virus assay, these nAbs are effective in blocking viral entry to the host cells.Conclusion:
This simple and efficient method may be useful in developing human therapeutic antibodies for other diseases and next pandemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Language:
English
Journal:
Antib Ther
Year:
2023
Document Type:
Article
Affiliation country:
Abt
Similar
MEDLINE
...
LILACS
LIS